Approval · Notice of Compliance 15622 · 2014
ALMOTRIPTAN: Notice of Compliance 15622
Issued May 22, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15622
- Date
- May 22, 2014
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Licensing agreement between two companies
- Therapeutic class
- 5-ht1 receptor agonist; migraine therapy
- Canadian reference product
- AXERT (Mcneil Consumer Healthcare)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ALMOTRIPTAN | 02424029 | Marketed |
Medicinal ingredients
- ALMOTRIPTAN MALATE 12.5 MG per TAB